It’s time to end overly restrictive eligibility criteria for cancer clinical trials, says Mikkael Sekeres, MD, MS. A new study offers a first step.
Dr. Sekeres offers concrete measures toward a repaired relationship between Contract Research Organizations and scientific investigators.
Even when patients, doctors and health systems emphasize time to treat, insurance processes can delay treatment.
In the first episode of the American Medical Association’s Doc Talk podcast, Timothy Gilligan, MD, and Mikkael Sekeres, MD, discuss how they provide comfort and guidance to patients facing death.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
How an oncologist’s experience caring for his mother during lung cancer diagnosis and treatment prompted three resolutions for future interactions with patients.
Mikkael Sekeres, MD, MS, played an unfamiliar role in a familiar setting when his mother was diagnosed with lung cancer.
Mikkael Sekeres, MD, MS, only understood his father’s passion for art on canvas after his father’s deteriorating health revealed the passion’s purpose.
The FDA has approved the immunocellular therapy for use in children and young adults with relapsed/refractory B-cell precursor ALL.
The Director of Cleveland Clinic’s Leukemia Program argues that we must define trial outcomes that matter to patients.
Early trial data show that precision therapy enasidenib can induce durable complete remission in patients with relapsed/refractory acute myeloid leukemia.